Convalescent Plasma
/ Royal College of Surgeons in Ireland
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
August 24, 2022
Epidemiology of Neonatal COVID-19 in the United States.
(PubMed, Pediatrics)
- "Most neonates infected with SARS-CoV-2 were asymptomatic or developed mild illness without need for respiratory support. Some neonates had severe illness requiring treatment for COVID-19 with remdesivir and CCP. Thus, SARS-CoV-2 infection in neonates, though rare, may result in severe disease."
Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
November 24, 2021
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.
(PubMed, BMC Infect Dis)
- "Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care."
Clinical • Journal • Retrospective data • Review • Critical care • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
May 13, 2021
Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease.
(PubMed, Sci Rep)
- P=N/A | "There were no significant differences in the primary or secondary outcome measures between CP and standard therapy, although a larger definitive study is needed for confirmation. However, the study did show that CP therapy appears to be safe in hospitalized COVID-19 patients with hypoxia.Clinical trials registration NCT04356534: 22/04/2020."
Clinical • Journal • Infectious Disease • Novel Coronavirus Disease
April 07, 2021
An Overview of Current Knowledge of Deadly CoVs and Their Interface with Innate Immunity.
(PubMed, Viruses)
- "Despite the rapid application of a range of therapies for SARS-CoV-2, such as convalescent plasma, remdesivir, hydroxychloroquine and type I interferon, no fully effective treatment has been determined. Here, we summarise an up-to-date understanding of epidemiology, immunomodulation and ongoing anti-viral and immunosuppressive treatment strategies. Indeed, understanding the interplay between coronaviruses and the anti-viral immune response is crucial to identifying novel targets for therapeutic intervention, which may even prove invaluable for the control of future emerging coronavirus."
Journal • Review • Acute Respiratory Distress Syndrome • Immune Modulation • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases
August 07, 2020
Convalescent Plasma Trial in COVID -19 Patients
(clinicaltrials.gov)
- P=N/A; N=40; Completed; Sponsor: Royal College of Surgeons in Ireland - Medical University of Bahrain; Recruiting ➔ Completed
Clinical • Trial completion • Infectious Disease • Novel Coronavirus Disease • CRP
May 14, 2020
Convalescent Plasma Trial in COVID -19 Patients
(clinicaltrials.gov)
- P=N/A; N=40; Recruiting; Sponsor: Royal College of Surgeons in Ireland - Medical University of Bahrain; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • CRP
1 to 6
Of
6
Go to page
1